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The proto-oncogene c-Myc is overexpressed in 70% of colorectal tumours and can modulate proliferation and apoptosis after
cytotoxic insult. Using an isogenic cell system, we demonstrate that c-Myc overexpression in colon carcinoma LoVo cells resulted in
sensitisation to camptothecin-induced apoptosis, thus identifying c-Myc as a potential marker predicting response of colorectal
tumour cells to camptothecin. Both camptothecin exposure and c-Myc overexpression in LoVo cells resulted in elevation of p53
protein levels, suggesting a role of p53 in the c-Myc-imposed sensitisation to the apoptotic effects of camptothecin. This was
confirmed by the ability of PFT-a, a specific inhibitor of p53, to attenuate camptothecin-induced apoptosis. p53 can induce the
expression of p21
Waf1/Cip1, an antiproliferative protein that can facilitate DNA repair and drug resistance. Importantly, although
camptothecin treatment markedly increased p21
Waf1/Cip1 levels in parental LoVo cells, this effect was abrogated in c-Myc-
overexpressing derivatives. Targeted inactivation of p21
Waf1/Cip1 in HCT116 colon cancer cells resulted in significantly increased levels
of apoptosis following treatment with camptothecin, demonstrating the importance of p21
Waf1/Cip1 in the response to this agent.
Finally, cDNA microarray analysis was used to identify genes that are modulated in expression by c-Myc upregulation that could serve
as additional markers predicting response to camptothecin. Thirty-four sequences were altered in expression over four-fold in two
isogenic c-Myc-overexpressing clones compared to parental LoVo cells. Moreover, the expression of 10 of these genes was
confirmed to be significantly correlated with response to camptothecin in a panel of 30 colorectal cancer cell lines.
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The tumour-suppressor gene p53 plays a pivotal role in determin-
ing cell fate after cytotoxic insult with DNA-damaging agents. p53
is a transcription factor that can either trigger an apoptotic cell
death by transcriptionally modulating multiple target genes, or
promote cell cycle arrest, and thus facilitate DNA damage repair,
through the upregulation of the cyclin-dependent kinase (cdk)
inhibitor p21
Waf1/Cip1 (el-Deiry et al, 1993; Miyashita et al, 1994).
Recently, levels of the proto-oncogene c-Myc have been shown to
be critical in switching the p53-dependent response from cell cycle
arrest to apoptosis after gamma radiation or treatment with
daunorubicin (Seoane et al, 2002), a topoisomerase II inhibitor
that is not frequently used for the treatment of colorectal
malignancies (Harvey et al, 1985). These effects are mediated
through the ability of c-Myc to interact with Miz-1 and down-
regulate the expression of p21
Waf1/Cip1, thus favouring the
proapoptotic activities of p53. Previously, we demonstrated the
clinical value of c-myc as a marker that predicts response to
treatment with 5-fluorouracil (5FU), the standard chemotherapeu-
tic agent used in the treatment of colorectal cancer (O’Dwyer and
Stevenson, 1998). Low-level amplification of c-myc, together with a
wild-type p53 gene, identified a subset of patients with locally
advanced colorectal cancer showing increased disease-free and
overall survival in response to 5FU-based adjuvant therapy
(Augenlicht et al, 1997; Arango et al, 2001).
Camptothecin is a topoisomerase I inhibitor that interferes with
DNA replication and transcription by stabilising the covalent
complex formed between Topoisomerase I and DNA. The
camptothecin derivative CPT-11 (Irinotecan) has been shown to
be a useful chemotherapeutic agent for the treatment of colorectal
cancer patients, improving response rates and survival when used
in combination with 5FU, and has also been shown to be effective
in 5FU-resistant tumours (Cunningham et al, 1998; Douillard et al,
2000; Arango and Augenlicht, 2001). Recently, there has been
significant progress in the identification of genetic markers that
allow prediction of response to 5FU and/or oxaliplatin, which
together with CPT-11 are the main chemotherapeutic agents used
in the treatment of colorectal cancer (Augenlicht et al, 1997;
Salonga et al, 2000; Arango et al, 2001, 2003; Park et al, 2001;
Shirota et al, 2001). However, there is great need for markers
predicting the efficacy of CPT-11 treatment. In this study, we
hypothesised that the levels of c-Myc could modulate the cellular
response to camptothecin. Using an in vitro isogenic system, we
demonstrated the important role of c-Myc in the apoptotic
response of colon cancer cells to camptothecin. Understanding
of the molecular mechanisms underlying this observation would
allow significant insight to be gained into the key determinants of
response to chemotherapy and could identify new targets for
intervention. Here we demonstrate a p53-dependent component in Received 3 July 2003; revised 27 August 2003; accepted 28 August 2003
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sthe c-Myc-imposed sensitisation to camptothecin-induced apop-
tosis. Moreover, forced expression of c-Myc resulted in reduced
levels of p21
Waf1/Cip1 despite elevated levels of p53, and targeted
inactivation of p21
Waf1/Cip1 resulted in increased sensitivity to
apoptosis induced by this agent.
Finally, to identify additional markers capable of predicting
apoptotic response to this agent, we used a cDNA microarray
analysis approach. The levels of expression of 9216 sequences were
assessed in camptothecin-resistant LoVo colon carcinoma cells
and camptothecin-sensitive isogenic derivatives overexpressing c-
Myc. Thiry-four sequences were identified exhibiting over 4-fold
difference in expression. The potential of 10 of these genes as
markers predicting response to camptothecin was confirmed by
the significant correlation observed between the levels of expres-
sion of these genes and the extent of apoptosis induced by
camptothecin in a panel of 30 different colorectal cancer cell lines.
MATERIALS AND METHODS
Cell lines and culture conditions
Colon adenocarcinoma LoVo cells and two isogenic clones
overexpressing c-Myc (L2 and L3) have been extensively
characterised and were maintained as described (Arango et al,
2001). TGR1 rat fibroblasts, isogenic HO15-19 cells with targeted
disruption of both alleles of c-myc, and HOmyc3 cells in which c-
Myc expression has been restored in the knockout cells (Mateyak
et al, 1997) were kindly provided by Dr Sedivy (Brown University,
RI, USA) and maintained with DMEM supplemented with 10% FBS
and 1  antibiotic/antimycotic (Invitrogen, Carlsbad, CA, USA).
HCT116, a colon carcinoma cell line with a functional p53 gene,
and an isogenic line with a targeted inactivation of p21
Waf1/Cip1
(Bunz et al, 1998) were kind gifts of Dr Vogelstein (Johns Hopkins
University School of Medicine). The panel of colorectal cancer cell
lines used was: Caco-2, Colo201, Colo205, Colo320, DLD-1,
HCT116, HCT-15, HCT-8, LoVo, LS174T, RKO, SK-CO-1,
SW1116, SW403, SW48, SW480, SW620, SW837, SW948, T84 and
WiDr (all from the American Type Culture Collection, Manassas,
VA, USA), HT29, HT29-Cl.16E, HT29-Cl.19A (from Dr Laboisse,
Institut National de la Sante et de la Recherche Medicale U539,
France (Augeron and Laboisse, 1984)), LIM1215, LIM2405 (from
Dr Whitehead, Vanderbilt University, Nashville, TN, USA (White-
head et al, 1985; Devine et al, 1992)), HCC2998, KM12 (from the
NCI-Frederick Cancer DCT tumour repository), RW2982 and
RW7213 (Tibbetts et al, 1988). All the colorectal cancer cell lines
were maintained in MEM supplemented with 10% FBS and 1 
antibiotic/antimycotic (Invitrogen, Carlsbad, CA, USA).
Quantification of apoptosis
1 10
5 cells were seeded in triplicate in six-well plates and 24h
later treated with the indicated concentrations of camptothecin
(Calbiochem, La Jolla, CA, USA). In some experiments, Pifithrin-a
(PFT-a; Calbiochem, La Jolla, CA, USA), a specific p53 inhibitor
(Komarov et al, 1999), was also added at time 0 (15–30mM). The
apoptotic response to camptothecin treatment was quantified after
72h by propidium iodide (PI) staining and assessment of the
proportion of cells with a subdiploid content of DNA by FACS
analysis, as described (Arango et al, 2001).
Western blot analysis
Both untreated and camptothecin-treated cultures (0.1 or 0.5mM
for 24h) growing in T75 flasks were rinsed twice with PBS,
harvested and the pellet resuspended in 300ml of RIPA buffer (1%
NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M
sodium phosphate pH 7.2, 2mM EDTA, 50mM sodium fluoride,
0.2mM sodium vanadate and 100Uml
 1 aprotinin), lysed for
30min on ice, and cleared by centrifugation. The appropriate
volume of Laemmli loading buffer (6 ) was added to 100mg
aliquots and fractionated in 15% SDS–polyacrylamide gels.
Proteins were transferred to a PVDF membrane (Amersham,
Piscataway, NJ, USA), blocked with 10% nonfat milk for 1h and
then probed at room temperature with the appropriate primary
antibody in 5% nonfat milk for 1h. The following antibodies and
dilutions were used: anti-p53 and anti-p21
Waf1/Cip1 (DO-1, 1/7000
and H-164, 1/200, respectively; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-b-actin (clone AC74, 1/1000; Sigma, Saint
Louis, MO, USA). Membranes were washed three times with
washing buffer (PBS with 0.1% Tween 20) and then probed with a
peroxidase-conjugated secondary antibody for 1h (Boehringer
Mannheim, Indianapolis, IN, USA). After washing three times with
washing buffer, the signal was detected using ECL plus (Amer-
sham, Piscataway, NJ, USA) and a Storm PhosphorImager
(Molecular Dynamics, Sunnyvale, CA, USA). The signal from the
b-actin probe was used as a loading control.
p21
Waf1/Cip1 promoter activity
p21
Waf1/Cip1 promoter activity was measured in parental LoVo cells
and c-Myc-transfected L2 and L3 cells using a transient transfec-
tion assay. The p21P construct (Datto et al, 1995) has a 2.4kb
insert containing the p21
Waf1/Cip1 promoter sequences in pGL2-
basic (Promega, Madison, WI, USA), driving transcription of a
firefly luciferase reporter gene. LoVo, L2 and L3 cells (5 10
4 per
well) were seeded in 24-well plates and cotransfected with p21P
and TK-Renilla (Promega, Madison, WI, USA) 24h later using
GenePORTER II (Gene Therapy Systems, San Diego, CA, USA).
After 48h, cells were harvested, and firefly and Renilla luciferase
activity levels assessed using the Dual Luciferase kit (Promega,
Madison, WI, USA) according to the manufacturer’s specifications.
In addition, parental LoVo cells were cotransfected with both p21P
and TK-Renilla as well as either p290-Myc(2,3), a c-Myc expression
vector (Reed et al, 1989) or the empty p290 vector, to assess the
effects of exogenous c-Myc on p21
Waf1/Cip1 promoter activity. In all
cases, values from TK-Renilla luciferase activity were used to
correct for differences in transfection efficiency.
Microarray analysis
Parental LoVo cells as well as L2 and L3 c-Myc transfectants
(5 10
6 cells) were seeded in T150 flasks, and harvested after 96h.
Total RNA was prepared using the RNeasy Midi kit (Qiagen,
Valencia, CA, USA). RNA aliquots (100mg) were reverse-tran-
scribed and labelled with Cy5 as described (Mariadason et al,
2000). All experimental samples were compared to a common
reference RNA resulting from mixing equal amounts of total RNA
from 12 different colon carcinoma cell lines. Reference RNA
aliquots (100mg) were reverse-transcribed and labelled with Cy3 in
parallel with the corresponding experimental samples, and then
combined and hybridised to a 9216-sequence cDNA microarray
from the Albert Einstein Cancer Center Microarray Facility, as
described (Mariadason et al, 2000). Microarray slides were
scanned and GenePix Pro 3.0 (Axon Instruments, Foster City,
CA, USA) was used to quantify signal and background in the Cy5
and Cy3 channels for each spot, as well as the Cy5/Cy3 signal ratio
and a normalisation factor that centred the average ratios over the
slide on 1. These data were transferred to a Microsoft Excel
spreadsheet, and normalised among arrays by multiplying the Cy5/
Cy3 ratio by the normalisation factor, thereby allowing interarray
comparison. All experiments were done in duplicate, beginning
with different RNA preparations. Data from both hybridisations
were averaged and used for subsequent analysis if there was a
significant level of expression (defined as signal4background plus
two standard deviations in the Cy5 and/or Cy3 channel). Relative
expression between LoVo and either L2 or L3 cells was calculated
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sby dividing the corresponding average values for each sequence.
These values were entered into Microsoft Access and sequences
with a difference in expression greater than four-fold between
LoVo, and both L2 and L3 were identified. GeneCluster and
TreeView software (Stanford University) were used to visualise the
results.
Quantitative real-time RT–PCR
The expression levels of 14 genes randomly selected from those
identified as differentially expressed (over four-fold) in microarray
experiments were confirmed using quantitative real-time RT–
PCR. RNA aliquots (5mg) from the same preparations used for the
microarray experiments were reverse transcribed using Super-
Script II (Invitrogen, Carlsbad, CA, USA). PCR primers for specific
target genes were designed using Primer Express software (Applied
Biosystems, Foster City, CA, USA) and used to quantify the relative
gene expression (see Table 1; primer sequences available at
www.realtimeprimers.org). 10ng cDNA aliquots from LoVo, L2
and L3 cells were amplified with specific primers using the SYBR
green Core Reagents Kit and a 7900HT real-time PCR instrument
(Applied Biosystems, Foster City, CA, USA). Expression of each
gene was standardised using GAPDH as a reference, and relative
levels in LoVo, L2 and L3 cells were quantified calculating 2 DDCT,
where DDCT is the difference in CT (cycle number at which the
amount of amplified target reaches a fixed threshold) between
target and reference, relative to parental LoVo cells.
RESULTS
Overexpression of c-Myc sensitises colon carcinoma cells
to apoptosis induced by camptothecin
To investigate the possible role of c-Myc in determining the
apoptotic response of colon cancer cells to camptothecin, we used
an isogenic in vitro system engineered by stably introducing a c-
Myc expression vector into the LoVo colon cancer cell line
(Arango et al, 2001). Two different derivative clones, L2 and L3,
have been extensively characterised and shown to have c-Myc
levels three- and eight-fold higher than parental LoVo cells,
respectively, and correspondingly increased c-Myc transactivation
activity levels (Arango et al, 2001). Quantification of the number of
apoptotic cells after exposure to 100 or 1000nM camptothecin for
72h demonstrated that the higher c-Myc levels in L2 and L3 cells
resulted in significantly (Po0.0001) increased apoptosis induced
by this agent (Figure 1).
To further confirm the observed c-Myc-induced sensitisation to
the apoptotic effects of camptothecin, we used TGR1 rat fibroblasts
and their derivative, HO15-19 cells, which contain a homozygous
deletion of the c-myc gene (Mateyak et al, 1997). In agreement with
Table 1 Genes differentially expressed in parental LoVo cells and c-Myc-overexpressing L2 and L3 isogenic cells
Microarray
a RT–PCR
b Correlation
c
Accession Gene name Function L2/L L3/L L2/L L3/L rP
AA088861 Cadherin 17, LI cadherin (liver–intestine) Cell adhesion 0.23 0.18 0.006 0.023  0.16
AA130579 Lectin, galactoside-binding, soluble, 4 (galectin 4) Cell adhesion 7.14 10.89 0.33
N30868 Integrin, alpha 4 Cell adhesion 4.75 6.87 0.48 0.016
R60995 Coagulation factor C homologue, cochlin Cell communication 0.12 0.17  0.54 0.002
AA453783 Mal, T-cell differentiation protein 2 Development–differentiation 6.26 4.5 0.35
H17696 Myelin basic protein Development–differentiation 12.03 10.41 0.260 0.350  0.09
AA290737 Glutathione S-transferase M1 Drug metabolism/resistance 0.17 0.25 0.002 0.012  0.43 0.019
H29521 ATP-binding cassette 3 Drug metabolism/resistance 0.14 0.19 0.003 0.001  0.09
H88329 Calbindin 1, (28kDa) Drug metabolism/resistance 0.11 0.1 0.004 0.001 0.00
AA664101 Aldehyde dehydrogenase 1 family, member A1 Drug metabolism/resistance 44.09 28.97 832 1137 0.49 0.006
AA031513 Matrix metalloproteinase 7 (matrilysin, uterine) Extracellular matrix 20.68 17.23  0.06
AA056013 Microfibril-associated glycoprotein-2 Extracellular matrix 0.19 0.2 0.11
AA479199 Nidogen 2 Extracellular matrix 0.21 0.22 0.004 0.002  0.14
AA458965 Natural killer cell transcript 4 Immune/inflammatory 0.08 0.16  0.07
AA682631 Calcineurin A alpha Kinase/phosphatase 0.23 0.24  0.28
AA431773 Fatty acid desaturase 1 Lipid metabolism 0.18 0.21 0.005 0.007  0.59 0.001
AA432066 Sarcoglycan, epsilon Metabolism 0.23 0.2  0.12
AA434024 Lanosterol synthase Metabolism 0.23 0.24 0.101 0.210  0.14
AA401137 Lipocalin 2 (oncogene 24p3) Oncogene 10.98 8.89 0.12
AA045436 Basic leucine zipper transcription factor MafG Oncogene 5.07 4.33 1.370 4.820  0.15
N63943 Lysozyme (renal amyloidosis) Antimicrobial 10.01 8.18 2161.8 1817.5 0.55 0.002
AA134814 TRAF family member-associated NFKB activator Signal transduction 4.83 4.44 0.55 0.013
AA598567 Myelin gene expression factor 2 Transcriptional coactivator 5.02 4.85  0.05
AA055486 Tripartite motif-containing 29 Transcription factor 5.35 4.84  0.10
AI017703 Eukaryotic translation initiation factor 3, subunit 3 Translation/AA biochemistry 5.11 4.25 0.45 0.013
R38343 Protein tyrosine phosphatase, receptor type, G Transmembrane receptor 0.23 0.18  0.16
T89391 Caveolin 2 Tumour suppressor 0.19 0.22 0.025 0.067  0.01
AA112057 KIAA0143 protein Unknown 6.73 5.57 0.40 0.031
AA282134 OK/SW-cl.68 mRNA, complete cds Unknown 16.06 10.51 774.2 568.4 0.12
AA702350 Autism-related protein 1 Unknown 0.06 0.08  0.04
AA702949 KIAA0443 gene product Unknown 0.11 0.16  0.06
R40481 cDNA FLJ34699 fis, clone MESAN2002186 Unknown 6.57 4.55 0.39 0.037
T62854 Hypothetical protein FLJ22662 Unknown 0.14 0.19 0.06
W16832 Muscleblind-like protein MBLL39 Unknown 4.48 4.93 39.1 87.0 0.19
Genes with significant correlations between their expression levels and apoptotic response to camptothecin in a panel of 30 colorectal cancer cell lines are shown in bold font.
aThe relative mRNA levels are shown for the 34 genes with a difference in expression greater than four-fold in LoVo vs L2 and L3 in the microarray experiments (mean of two
experiments).
bThe relative expression levels are measured using quantitative real-time RT–PCR for 14 of these 34 genes.
cPearson’s correlation for gene expression and
response to camptothecin in 30 colorectal cancer cell lines.
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sthe results obtained using the LoVo system, the apoptotic response
of TGR1 cells to camptothecin was significantly (Po0.025)
reduced in c-Myc-deficient HO15-19 isogenic cells exposed for
72h to concentrations of camptothecin ranging from 25 to 100nM
(Figure 2A,B). Moreover, when c-Myc expression was rescued in
HO15-19 cells (HOmyc3 cells), their response to camptothecin
returned to that observed in parental TGR1 cells (Figure 2A,B).
Collectively, these results demonstrate an important role for c-Myc
in the apoptotic response to camptothecin.
Role of p53 in c-Myc-imposed sensitisation to
camptothecin-induced apoptosis
c-Myc has been shown to regulate p53 levels both directly and
through modulation of p19
ARF (Reisman et al, 1993; Tavtigian et al,
1994; Zindy et al, 1998). In addition, p53 has been reported to
modulate the cellular response to several chemotherapeutic agents,
including camptothecin and its derivatives (Gupta et al, 1997; Yang
et al, 1996). Therefore, to investigate the possible role of p53 in the
increased apoptotic response to camptothecin imposed by c-Myc
overexpression, we assessed the relative levels of this tumour
suppressor in p53 wild-type LoVo cells and c-Myc-transfected
clones L2 and L3. c-Myc overexpression in L2 and L3 cells resulted
in markedly increased p53 protein levels (Figure 3), consistent
with the chemosensitive phenotype of these cells. Moreover,
treatment of parental LoVo cells with 0.1 or 0.5mM camptothecin
for 24h lead to modestly increased p53 levels (Figure 4). However,
Figure 4 shows that p53 levels in camptothecin-treated parental
LoVo cells remained significantly lower than in untreated L2 and
L3 cells. To directly assess the functional role of p53 in
camptothecin-induced apoptosis, c-Myc-overexpressing L2 and
L3 cells were exposed to camptothecin in the presence of doses of
PFT-a, a specific inhibitor of p53 (Komarov et al, 1999), that we
have previously shown to inhibit 5FU-induced apoptosis in this
system (Arango et al, 2001). Here, inhibition of p53 function
resulted in over 50% reduction in the apoptotic response to 0.5mM
camptothecin, demonstrating a p53-dependent component in the
c-Myc-dependent increase in apoptosis following treatment with
this agent (Figure 5).
Role of p21
Waf1/Cip1 in c-Myc-imposed sensitisation to
camptothecin-induced apoptosis
p53 can strongly induce apoptosis by transcriptionally regulating
the expression of a number of key players in the apoptotic cascade
(Miyashita et al, 1994). However, p53 can alternatively induce cell
cycle arrest and promote DNA damage repair through upregula-
tion of the cdk inhibitor p21
Waf1/Cip1 (el-Deiry et al, 1993). c-Myc
overexpression in LoVo cells resulted in significantly increased p53
levels, which could lead to increased p21
Waf1/Cip1 levels. However,
c-Myc has been shown to directly downregulate p21
Waf1/Cip1 levels
(Mitchell and El-Deiry, 1999; Gartel et al, 2001). Therefore, we
decided to assess the overall effects of c-Myc overexpression on the
transcriptional activity of the p21
Waf1/Cip1 promoter. First, we
investigated whether c-Myc can reduce p21
Waf1/Cip1 promoter
activity in parental LoVo cells. Cotransfection of a c-Myc
expression vector and a construct containing the p21
Waf1/Cip1
promoter region upstream of a luciferase reporter gene (p21P
plasmid), demonstrated that c-Myc could effectively reduce the
promoter activity of p21
Waf1/Cip1 in LoVo cells (Figure 6A). Next,
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Figure 1 c-Myc overexpression sensitises colon cancer cells to
camptothecin-induced apoptosis. The higher c-Myc levels and activity
found in LoVo cells transfected with c-Myc (L2 and L3 cells) resulted in
significant sensitisation to camptothecin-induced apoptosis, as demon-
strated by PI staining and FACS analysis of cells exposed to 100 or 1000nM
camptothecin. The mean of three experiments7standard error of the
mean is shown. Asterisks indicate significant differences (Student’s t-test;
Po0.0001) between L2 or L3 cells and parental LoVo cells.
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Figure 2 c-Myc levels modulate the apoptotic response to camptothe-
cin in TGR1 cells. Panel (A) shows representative phase-contrast
micrographs of TGR1 cells and derivatives exposed to 100nM camptothe-
cin for 72h. In panel (B), the apoptotic response to camptothecin was
quantified by PI staining and FACS analysis. Targeted deletion of the c-Myc
gene in TGR1 cells (HO15-19 cells) results in a significant reduction in
camptothecin-induced apoptosis (A,B). Restoring c-Myc expression in c-
Myc-deficient HO15-19 cells (HOmyc-3 cells) results in a significant
increase in apoptosis. The mean of three experiments7standard error of
the mean is shown in panel (B). Asterisks indicate significant differences
(Student’s t-test; Po0.025) between c-Myc null HO15-19 cells and both
parental TGR1 cells and c-Myc rescue HOmyc-3 cells for a given dose.
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swe compared p21
Waf1/Cip1 promoter activity in parental LoVo cells
and L2 and L3 cells showing elevated levels of c-Myc and p53. The
promoter activity of p21
Waf1/Cip1 was found to be significantly
reduced in L2 and L3 cells compared to parental LoVo cells (1.75-
and 2.5-fold downregulation, respectively; Figure 6B). Consistent
with the reduced transcriptional activity of the p21
Waf1/Cip1
promoter, Western blot analysis demonstrated that the higher c-
Myc levels in LoVo transfectants (L2 and L3 cells) resulted in a
significant reduction in p21
Waf1/Cip1 protein (Figure 3), despite the
higher p53 levels.
Importantly, although exposure of parental LoVo cells to 0.1 or
0.5mM camptothecin for 24h resulted in upregulation of p53 and
the p53 target gene p21
Waf1/Cip1, c-Myc-overexpressing L2 and L3
cells failed to upregulate p21
Waf1/Cip1 protein levels in response to
camptothecin treatment (Figure 4), strongly suggesting that
p21
Waf1/Cip1 levels could modulate apoptosis induced by camp-
tothecin. To directly investigate this possibility, we used an
engineered in vitro system where both alleles of the p21
Waf1/Cip1
gene have been inactivated by targeted deletion in HCT116 cells, a
colon cancer cell line with a wild-type p53 gene (Bunz et al, 1998).
Inactivation of p21
Waf1/Cip1 in these cells resulted in significantly
(Po0.004) increased sensitivity to apoptosis induced by camp-
tothecin compared to parental wild-type p21
Waf1/Cip1 HCT116 cells
(Figure 7), further demonstrating a role for p21
Waf1/Cip1 in
regulating response of colon cancer cells to camptothecin.
Identification of additional markers predicting response to
camptothecin
To identify additional genes that could serve as markers predicting
apoptotic response to camptothecin, we measured the relative
expression of 9216 sequences, in duplicate, in resistant LoVo cells,
as well as in sensitive c-Myc-overexpressing L2 and L3 isogenic
cells, using cDNA microarray analysis. The complete databases are
available at http://sequence.aecom.yu.edu/bioinf/Augenlicht/de-
fault.html. First, to assess the background variability due to
methodological and biological factors, we averaged the values for
the two LoVo replicas and compared them to the average of
another two different replicates of LoVo cells, and quantified the
number of genes identified as differentially expressed as a function
of selected cutoff values (Figure 8A). Using a conservative cutoff
value of four-fold, there were six sequences that would be
considered differentially expressed between the two pairs of LoVo
replicas. However, using the same four-fold cutoff, LoVo vs L2 and
LoVo vs L3 differed in the expression of 63 and 47 genes,
respectively. Moreover, 34 of those genes were differentially
expressed over four-fold in both L2 and L3 compared to parental
LoVo cells (Figure 8B; Table 1).
Utilisation of a four-fold change in expression for gene selection
greatly minimises the probability of false positives. This was
confirmed by quantitative real-time RT–PCR analysis of the
relative expression levels of 14 of the 34 genes identified as
differentially expressed by the microarray analysis. Good qualita-
tive agreement was observed in changes in the levels of expression
assessed by microarray and real-time RT–PCR for 13 out of the 14
genes tested by the two methods (Table 1). However, as observed
in other studies (Sgroi et al, 1999; Menssen and Hermeking, 2002;
Reinhold et al, 2003), the magnitude of the differences in gene
expression assessed by quantitative real-time RT-PCR was greater
than those observed using a cDNA microarray approach (Table 1).
Although a subset of the 34 genes differentially expressed over
four-fold in LoVo cells and c-Myc-overexpressing L2 and L3 cells
is likely to play a role in their differential apoptotic response to
LoVo
L2
L3
p21
-Actin
p53
Figure 3 Effects of c-Myc overexpression on p53 and p21
Waf1/Cip1
levels. Western blot analysis demonstrated that forced overexpression of c-
Myc in LoVo cells (L2 and L3 cells) results in increased p53 and reduced
p21
Waf1/Cip1 protein levels.
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Figure 4 Effects of camptothecin treatment on p53 and p21
Waf1/Cip1
levels. Western blot analysis demonstrated that exposure to 0.1–0.5mM
camptothecin for 24h results in a modest induction of p53 and significant
accumulation of p21
Waf1/Cip1 in parental LoVo cells. Overexpression of c-
Myc in L2 and L3 cells completely abrogates upregulation of p21
Waf1/Cip1
levels in response to camptothecin, despite the elevated p53 levels.
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Figure 5 Role of p53 in the c-Myc imposed sensitisation to
camptothecin-induced apoptosis. Exposure of L2 and L3 cells to
camptothecin for 72h in the presence of the specific inhibitor of p53
PFT-a demonstrated a p53-dependent component in their increased
apoptotic response to this agent compared to parental LoVo cells. Mean of
three experiments7standard error of the mean.
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scamptothecin, elevated c-Myc levels have been shown to affect
other phenotypic characteristics of colon cancer cells, including
cell cycle progression and basic metabolism (Tikhonenko et al,
1996; Dang, 1999; Menssen and Hermeking, 2002). Therefore, the
subset of genes that may be specific markers of response to
camptothecin is not clear. To identify this subset of genes, we
screened the expression of these 34 sequences in a separate
microarray database containing the expression profile of 30
different colorectal cancer lines assessed using the same 9216-
sequence cDNA chips (Mariadason et al, 2003; the full database is
available at http://sequence.aecom.yu.edu/bioinf/Augenlicht/de-
fault.html). In addition, we have determined the relative sensitivity
of these cell lines to camptothecin-induced apoptosis (percent
apoptosis after 72h exposure to 1mM camptothecin; Mariadason
et al, 2003). Of the 34 genes that varied in expression over four-
fold in parental LoVo cells and c-Myc-overexpressing L2 and L3
cells, 10 showed a significant correlation (R40.39; Po0.037)
between expression levels and response to camptothecin in each of
the 30 colorectal cancer cell lines in our panel (Table 1). As a
control, we selected the 34 genes showing the least difference in
expression between resistant LoVo cells and sensitive L2 and L3
cells. None of these genes showed a significant correlation between
expression levels and apoptotic response to camptothecin in the
panel of 30 colorectal cancer cell lines (not shown), highlighting
the potential of the genes modulated by c-Myc as biomarkers of
response to camptothecin.
DISCUSSION
The proto-oncogene c-Myc is overexpressed in approximately 70%
of colorectal tumours (Erisman et al, 1985). Deregulation and
overexpression of c-Myc and other oncogenes, in addition to
having proliferative effects, is frequently associated with an
apoptosis-prone phenotype, thus opening the possibility of
therapeutic intervention (Prendergast, 1999). This study demon-
strates that upregulation of c-Myc levels and activity in colon
cancer cells results in markedly increased sensitivity to apoptosis
induced by camptothecin. Forced overexpression of c-myc in LoVo
colon cancer cells, induced significant accumulation of p53, and
the increased apoptotic response to camptothecin was at least
partially dependent upon p53 function. However, p53 can induce
cell cycle arrest and facilitate DNA damage repair through the
transcriptional activation of the cdk inhibitor p21
Waf1/Cip1. The
factors determining a p53-dependent apoptotic or cytostatic
response to cytotoxic insult remain unclear. Recently, elevated c-
Myc levels have been identified as one such factor favouring a p53-
dependent apoptotic response (Seoane et al, 2002). Here we show
that despite the elevated p53 levels in c-Myc-overexpressing L2 and
L3 cells compared to parental LoVo cells, c-Myc directly repressed
the transcriptional activity of p21
Waf1/Cip1 and resulted in reduced
p21
Waf1/Cip1 protein levels. Moreover, although camptothecin
treatment resulted in p21
Waf1/Cip1 accumulation in resistant LoVo
cells, sensitive L2 and L3 cells failed to upregulate p21
Waf1/Cip1
levels in the presence of camptothecin. The functional relevance of
this finding was further demonstrated using an isogenic in vitro
system in which both alleles of p21
Waf1/Cip1 were inactivated by
homologous recombination in HCT116 cells. Inactivation of
p21
Waf1/Cip1 in HCT116 cells resulted in significantly increased
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Figure 6 effects of c-Myc on p21
Waf1/Cip1 promoter activity. (A)
Parental LoVo cells were transfected with a vector containing the
p21
Waf1/Cip1 promoter sequences upstream of a Firefly Luciferase reporter
gene (p21P) and a c-Myc expression vector (p290-Myc). This demon-
strated a c-Myc-dependent reduction in p21
Waf1/Cip1 promoter activity
when compared to cells transfected with p21P and p290 empty vector
(two-fold). Additional controls showed that transfection of LoVo cells with
pGL2 (p21P without the p21
Waf1/Cip1 promoter sequence) and either p290
or p290-Myc resulted in minimal luciferase activity. (B) LoVo, L2 and L3
cells were transfected with p21P to measure the differences in promoter
activity. The increased c-Myc levels in L2 and L3 resulted in a c-Myc dose-
dependent reduction of p21
Waf1/Cip1 promoter activity. Relative c-Myc
mRNA levels are shown underneath the histogram. Cotransfection with
the plasmid TK-Renilla was used to correct for differences in transfection
efficiency. The experiments were done three times in triplicate, and results
of a representative experiment are shown.
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Figure 7 Role of p21 in the apoptotic response to camptothecin.
Targeted inactivation of both alleles of p21
Waf1/Cip1 in HCT116 colon
cancer cells resulted in significant sensitisation to camptothecin-induced
apoptosis. The mean of four different experiments7standard error of the
mean is shown. Asterisks indicate significant differences (Student’s t-test,
Po0.004) between apoptotic levels in HCT116 p21þ/þ and  /  for a
given dose.
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sapoptosis following camptothecin treatment compared to
p21
Waf1/Cip1 wild-type parental HCT116 cells. Collectively, these
studies identified the c-Myc-imposed reduction in p21
Waf1/Cip1
levels as an important factor determining the increased sensitivity
to camptothecin-induced apoptosis associated with elevated c-Myc
levels.
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Figure 8 cDNA microarray analysis of LoVo and isogenic L2 and L3 cells overexpressing c-Myc. (A) The number of genes identified as differentially
expressed is a function of the cutoff used. Selection of a stringent cutoff value of four-fold reduces the number of false positives expected when assessing
differences in gene expression between LoVo and L2/L3 cells. (B) TreeView image showing the expression profile of the 34 genes with over four-fold
expression difference between LoVo and L2/L3 that characterise camptothecin-resistant and -sensitive cells. Both replicas are shown. Red and green indicate
genes that are over-represented and under-represented, respectively, relative to the reference RNA used (see Materials and Methods).
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sDespite significant progress in the identification of markers
predicting response to other chemotherapeutic agents commonly
used in the treatment of colorectal malignancies, namely, 5FU and
oxaliplatin (Augenlicht et al, 1997; Salonga et al, 2000; Arango et al,
2001, 2003; Park et al, 2001; Shirota et al, 2001), there is a great
need for clinical predictors of response to camptothecin deriva-
tives. The capability of predicting response to the chemother-
apeutic agents available for the treatment of colorectal cancer
would allow tailoring of treatment to individual patients, thus
maximising the probability of optimal response to therapy. Here
we identified c-Myc as a marker predicting response to
camptothecin. Moreover, dissection of the molecular mechanisms
responsible for the c-Myc-imposed sensitisation to camptothecin
demonstrated the key role of p21
Waf1/Cip1 in determining response
of colon cancer cells to this agent, and pointed at this cdk inhibitor
as an additional predictor of response.
To gain further insight into the differences between colon
cancer cells that vary in their apoptotic response to camptothecin,
and to identify additional markers that could help recognise
tumours that vary in their response to this agent, we assessed
the level of expression of 9216 sequences in resistant LoVo cells,
and in sensitive L2 and L3 derivatives, using cDNA microarray
analysis. This identified 34 genes that varied in expression over
four-fold in parental LoVo cells and c-Myc-overexpressing L2 and
L3 cells. To determine which of these 34 genes are effective
predictors of the apoptotic response to camptothecin, we utilised a
database containing the levels of expression of the same 9216
sequences in a panel of 30 different colorectal cancer cell lines
using cDNA microarray analysis. In addition, we have also
determined the relative sensitivity of these 30 cell lines to
camptothecin. To identify those sequences associated with
differences in sensitivity to camptothecin, we assessed whether
each one of the 34 genes differentially expressed in resistant LoVo
and sensitive L2/L3 cells showed a significant correlation between
expression levels and camptothecin-induced apoptosis in the 30
cell lines in our panel. This identified 10 genes with significant
expression/response correlations (R40.39 and Po0.037; Table 1).
This list of candidate genes capable of predicting response to
camptothecin contains genes involved in drug metabolism/
resistance, signal transduction, protein translation and general
metabolism (see Table 1). At least some of these genes have been
shown to vary in expression in colorectal tumours, including GST-
M1, ALDH and lysozyme (Yuen et al, 1998; Saadat and Saadat,
2001), and could play a functional role in the cellular response
to camptothecin and its derivatives. Therefore, in addition to their
value as markers predicting response to camptothecin, each of
these genes could represent a new target for therapeutic
intervention.
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